Methylene Blue Uses: Clinical Evidence & Safety

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Methylene blue is a synthetic compound with redox properties used in psychiatry, infectious disease, and metabolic contexts. Originally developed as a textile dye in the 1800s, clinical research has identified multiple therapeutic pathways, though evidence strength varies by indication.

As precision medicine expands, understanding how methylene blue fits into broader metabolic and neurochemical strategies matters. PlexusDx supports patients exploring personalized approaches by connecting genetic predispositions with evidence-based treatment options and qualified provider guidance.

Clinical Applications of Methylene Blue

Methylene blue has been studied in psychiatry, primarily for major depression and bipolar disorder, often as an adjunctive agent. Research suggests it may modulate mitochondrial function and support antidepressant effects, though most studies involve small patient populations and require larger trials.

Beyond psychiatry, methylene blue has antimicrobial properties and is used in urinary tract infection contexts and methemoglobinemia reversal. Emerging research explores its role in cognitive support and mitochondrial health, though these applications remain investigational in most clinical settings.

Mechanism of Action and Metabolic Relevance

Methylene blue functions as a redox-active electron carrier, influencing cellular energy production at the mitochondrial level. This mechanism connects to metabolic pathways and may explain reported cognitive and mood-related effects in some patient populations.

Mechanism	Clinical Context
Redox cycling	Electron transport chain support and mitochondrial ATP production
Monoamine modulation	Potential serotonin and dopamine pathway effects in psychiatric use
Antimicrobial action	Direct bacterial inhibition in urinary and wound infection contexts
Neuroprotection	Emerging research on oxidative stress reduction in neurodegenerative conditions

Evidence Base and Current Research Limitations

Clinical evidence for methylene blue remains mixed. Depression studies show modest benefits in some trials, but sample sizes are typically small and heterogeneous. Larger, controlled trials are needed to establish efficacy thresholds and optimal dosing across psychiatric indications.

For infectious disease and methemoglobinemia, evidence is stronger and well-established. However, many metabolic and cognitive applications lack robust human data. Qualified providers should weigh potential benefits against evidence quality and individual patient factors when considering use.

Safety Considerations and Who Should Evaluate This Option

Methylene blue generally carries a favorable safety profile at therapeutic doses but interacts with serotonergic medications due to monoamine oxidase inhibition. Patients on SSRIs, MAOIs, or other serotonergic agents require careful provider assessment and possible dosing adjustments to reduce serotonin syndrome risk.

Individuals with glucose-6-phosphate dehydrogenase deficiency should avoid methylene blue due to hemolysis risk. Pregnant or breastfeeding patients, those with kidney or liver impairment, and patients on multiple medications should consult a qualified healthcare provider before use. Provider-guided decision-making is essential for safe, individualized therapy.

How PlexusDx Supports a More Personalized Approach

Methylene blue's mechanism on mitochondrial function relates to broader metabolic health—an area where genetic predispositions in energy metabolism pathways may provide context. PlexusDx's Precision Peptide Genetic Test reveals variants in FTO, GLP1R, GIPR, and MC4R that influence metabolic regulation. While methylene blue is not a GLP-1 pathway agent, understanding your genetic profile may help identify whether metabolic support strategies fit your overall treatment plan.

The Precision Peptide Genetic Test predicts predispositions in peptide signaling and metabolic pathways but does not predict exact methylene blue response or necessity. Genetic variants provide one data point among many—family history, biomarkers, clinical symptoms, and provider assessment remain essential. This information should be interpreted with a qualified healthcare provider in the context of comprehensive evaluation.

If you are considering methylene blue or exploring personalized metabolic strategies, discussing genetic insights with your provider can support more informed treatment planning. PlexusDx helps patients access genetic context to enable deeper conversations about precision wellness approaches, medication interactions, and long-term metabolic goals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $179-$229/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is methylene blue FDA-approved for depression?

Methylene blue is not FDA-approved as a primary depression treatment. Some evidence supports adjunctive use, but clinical practice remains limited. Provider evaluation is required; this remains an off-label consideration.

What is the typical dosing range for methylene blue in psychiatric use?

Psychiatric studies typically use 15–100 mg daily, often in divided doses. Dosing varies by indication and patient factors. A qualified provider should determine appropriate dosing and monitor response and side effects throughout therapy.

Can methylene blue interact with semaglutide or tirzepatide?

Direct interactions between methylene blue and compounded GLP-1 agents are not well-documented. However, methylene blue's serotonergic effects require careful evaluation if combined with other medications. Always inform your provider of all agents you are taking.

What are common side effects of methylene blue?

Common effects include blue-tinted urine and sclera, nausea, and headache. Serotonin syndrome is a serious risk when combined with serotonergic drugs. Serious adverse events are rare at therapeutic doses but require immediate provider attention if symptoms develop.

Does the Precision Peptide Genetic Test predict methylene blue response?

No. The test reveals predispositions in GLP-1R, GIPR, FTO, and MC4R peptide pathways—not methylene blue metabolism or efficacy. Genetic context can support broader metabolic planning but does not predict individual medication response across all agents.

What Is Methylene Blue Used For: Clinical Evidence and Patient Considerations

Methylene blue is a redox-active compound with multiple clinical applications ranging from psychiatric symptom management to infection treatment and mitochondrial support. Understanding its mechanisms, evidence base, and who may benefit requires qualified provider evaluation.